The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options FDA Peptide Update: Category 2 Removals Explained The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate AJMC